MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.630
-0.440
-8.68%
Opening 10:34 03/03 EST
OPEN
5.09
PREV CLOSE
5.07
HIGH
5.17
LOW
4.525
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
5.95
52 WEEK LOW
1.795
MARKET CAP
992.17M
P/E (TTM)
-12.1427
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Ziopharm Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 2d ago
What Made H.C. Wainwright Downgrade Ziopharm Oncology’s Stock?
In a report released today, Swayampakula Ramakanth from H.C. Wainwright downgraded Ziopharm Oncology (ZIOP) to Hold. The company's shares closed last
SmarterAnalyst · 2d ago
--Analyst Actions: HC Wainwright Downgrades ZIOPHARM Oncology to Neutral From Buy
MT Newswires · 2d ago
DJ Ziopharm Oncology, Inc. Price Target Is Maintained at $5.50/Share by Raymond James
Dow Jones · 4d ago
DJ Ziopharm Oncology, Inc. Is Maintained at Outperform by Raymond James
Dow Jones · 4d ago
Ziopharm Oncolog Shares Up 95.8% Since SmarTrend's Buy Recommendation (ZIOP)
Feb 26, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Ziopharm Oncolog (NASDAQ:ZIOP) on November 11th, 2020 at $2.65. In...
marketwatch.com · 4d ago
Ziopharm Oncology (ZIOP) Gets a Buy Rating from Raymond James
Raymond James analyst David Novak maintained a Buy rating on Ziopharm Oncology (ZIOP) today and set a price target of $5.50. The company's shares closed
SmarterAnalyst · 5d ago
DJ ZIOPHARM Oncology, Inc. CEO Laurence Cooper on Q4 2020 Results -- Earnings Call Transcript >ZIOP
Dow Jones · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZIOP. Analyze the recent business situations of ZIOPHARM Oncolgy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZIOP stock price target is 6.00 with a high estimate of 7.50 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 265
Institutional Holdings: 114.81M
% Owned: 53.58%
Shares Outstanding: 214.29M
TypeInstitutionsShares
Increased
38
8.72M
New
49
444.03K
Decreased
52
5.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.57%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Executive Director
James Huang
Chief Executive Officer/Director
Heidi Hagen
Chief Financial Officer
Timothy Cunningham
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Robert Hadfield
Executive Vice President/General Manager
Jill Buck
Vice President/Director of Investor Relations
David Connolly
Executive Vice President/General Manager
Eleanor De Groot
Executive Vice President/Director of Human Resources
Lynn Ferrucci
Senior Vice President - Finance/Chief Accounting Officer/Treasurer
Kevin Lafond
Other
Raffaele Baffa
Director
J. Kevin Buchi
Director
Robert Postma
Director
Jaime Vieser
Director
Holger Weis
Independent Director
Christopher Bowden
Independent Director
Mary Thistle
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Webull offers kinds of ZIOPHARM Oncology Inc. stock information, including NASDAQ:ZIOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZIOP stock methods without spending real money on the virtual paper trading platform.